Logo
x

Search

Subscribe Now

Gilead

Gilead Receives EC’s Conditional Marketing for Seladelpar to Treat Primary Biliary Cholangitis (PBC)

Gilead Receives EC’s Conditional Marketing for Seladelpar to Treat Primary Biliary Cholangitis (PBC)

  • February 21, 2025
Gilead Reports US FDA’s NDA Acceptance of Lenacapavir for Pre-Exposure Prophylaxis (PreP) to Prevent HIV in Individuals at Risk

Gilead Reports US FDA’s NDA Acceptance of Lenacapavir for Pre-Exposure Prophylaxis (PreP) to Prevent HIV in Individuals at Risk

  • February 19, 2025
Gilead and LEO Pharma Join Forces to Develop STAT6 Program for Multiple Inflammatory Disorders

Gilead and LEO Pharma Join Forces to Develop STAT6 Program for Multiple Inflammatory Disorders

  • January 13, 2025
Gilead and Terray Therapeutics Partner to Discover and Develop Small Molecules for Various Targets

Gilead and Terray Therapeutics Partner to Discover and Develop Small Molecules for Various Targets

  • December 18, 2024
Gilead Receives CHMP's Positive Opinion of Seladelpar to Treat Primary Biliary Cholangitis (PBC)

Gilead Receives CHMP's Positive Opinion of Seladelpar to Treat Primary Biliary Cholangitis (PBC)

  • December 13, 2024
US FDA Grants Accelerated Approval to Gilead’s Livdelzi (Seladelpar) to Treat Primary Biliary Cholangitis (PBC)

US FDA Grants Accelerated Approval to Gilead’s Livdelzi (Seladelpar) to Treat Primary Biliary Cholangitis (PBC)

  • August 16, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.